| Mountain View Health & Rehab | |
| 201 Koontz Lane, Carson City, Nevada 89701 | |
| (775) 883-3622 | |
| Name | Mountain View Health & Rehab |
|---|---|
| Location | 201 Koontz Lane, Carson City, Nevada |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 146 |
| Occupancy Rate | 70.07% |
| Medicare ID (CCN) | 295079 |
| Legal Business Name | Evergreen At Mountain View, L.l.c. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1144279472 |
| Organization Name | EVERGREEN AT MOUNTAIN VIEW, L.L.C. |
| Doing Business As | MOUNTAIN VIEW HEALTH AND REHABILITATION CENTER |
| Address | 201 Koontz Ln, Carson City, NV 89701 |
| Phone Number | 775-883-3622 |
News Archive
Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
Hypobaric hypoxia can cause severe brain damage and mitochondrial dysfunction, and is involved in hypoxic brain injury. Dr. Jianyu Li and colleagues from Logistics College of Chinese People's Armed Police Forces evaluated the degree of brain damage with different exposure times to hypoxia and further investigate the differential expression of cerebral mitochondrial proteins by comparative proteomic analysis, in a broader attempt to search for treatment targets of hypobaric hypoxia brain injury.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
Hypobaric hypoxia can cause severe brain damage and mitochondrial dysfunction, and is involved in hypoxic brain injury. Dr. Jianyu Li and colleagues from Logistics College of Chinese People's Armed Police Forces evaluated the degree of brain damage with different exposure times to hypoxia and further investigate the differential expression of cerebral mitochondrial proteins by comparative proteomic analysis, in a broader attempt to search for treatment targets of hypobaric hypoxia brain injury.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $13627 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.48 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.01 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 42.96 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.23 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.24 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.27 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.4 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.8 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 26.3 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 72.97 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.11 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 25.56 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.65 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.27 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 69.03 | 82.93 |
News Archive
Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Nearly two thirds of the states in the US saw a small decrease in mammography utilization between the years 2000 and 2006, according to a study performed at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
Hypobaric hypoxia can cause severe brain damage and mitochondrial dysfunction, and is involved in hypoxic brain injury. Dr. Jianyu Li and colleagues from Logistics College of Chinese People's Armed Police Forces evaluated the degree of brain damage with different exposure times to hypoxia and further investigate the differential expression of cerebral mitochondrial proteins by comparative proteomic analysis, in a broader attempt to search for treatment targets of hypobaric hypoxia brain injury.
› Verified 4 days ago
Carson Nursing And Rehabilitation Center Location: 2898 Highway 50 East, Carson City, Nevada 89701 Phone: (775) 882-3301 | |
Mountain View Health & Rehab Location: 201 Koontz Lane, Carson City, Nevada 89701 Phone: (775) 883-3622 | |
Carson Tahoe Transitional Rehabilitation Center Location: 1001 Mountain Street, Carson City, Nevada 89703 Phone: (360) 735-7155 |